BeyondSpring

BeyondSpring's Plinabulin Shows Promise in Overcoming Immunotherapy Resistance in NSCLC

- BeyondSpring's Phase 3 DUBLIN-3 study demonstrated that plinabulin combined with docetaxel achieved a statistically significant overall survival benefit with a hazard ratio of 0.72 (p=0.0078) in EGFR wild-type non-small cell lung cancer patients. - Early clinical data suggests plinabulin may restore sensitivity to checkpoint inhibitors in patients who have developed resistance, addressing a major unmet need affecting approximately 60% of patients on PD-1/PD-L1 therapies. - The company plans to initiate the global Phase 3 DUBLIN-4 confirmatory study focusing on EGFR wild-type non-squamous NSCLC patients who progressed on prior PD-1/L1 inhibitors. - BeyondSpring will present combination data on plinabulin with antibody-drug conjugates at the 2026 AACR Annual Meeting, expanding its therapeutic applications beyond checkpoint inhibitor combinations.